Tissue Dynamics and Galmed Pharmaceuticals to Develop HumanCentered Chronic Cardiac Fibrosis Platform to Advance AramcholBased Therapeutics
News Source : PRNewswire
News Summary
- Tissue Dynamics and Galmed are collaborating on the development of the new platform as a high-throughput, human-centered model of chronic cardiac fibrosis.
- The platform will combine Tissue Dynamics' highly physiological vascularized, multichambered cardiac organoids with embedded metabolic sensors, massive automation, and continuous real-time monitoring.
- By monitoring thousands of organoids over time and applying AI-powered analysis, the model is expected to support rapid evaluation of Aramchol-based therapeutic approaches.
Novel vascularized, sensorembedded cardiac organoid model will focus on chronic postMI remodeling and HFpEF, linking lipid metabolism, SCD1 activity, fibrosis, and impaired tissue repairREHOVOT, [+11741 chars]
Never miss a story from us, subscribe to our newsletter